213 related articles for article (PubMed ID: 32671986)
1. Polymyalgia rheumatica in a melanoma patient 11 months after completion of immunotherapy with nivolumab.
Lobo Y; Good P; Murphy F
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1244. PubMed ID: 32671986
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-Induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma.
Kita T; Araya T; Sakai T; Uchida Y; Matsuoka H; Kasahara K
Am J Med Sci; 2021 Sep; 362(3):321-323. PubMed ID: 33905737
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
5. Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V; Dunet V; Hottinger AF; Berthod G; Schiappacasse L; Peters S; Michielin O; Aedo-Lopez V
J Immunother Cancer; 2019 Dec; 7(1):336. PubMed ID: 31791418
[TBL] [Abstract][Full Text] [Related]
6. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.
Mooradian MJ; Nasrallah M; Gainor JF; Reynolds KL; Cohen JV; Lawrence DP; Miloslavsky EM; Kohler MJ; Sullivan RJ; Schoenfeld SR
Semin Arthritis Rheum; 2019 Jun; 48(6):1127-1132. PubMed ID: 30409415
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogression after nivolumab for melanoma: A case report.
Yilmaz M; Akovali B
J Oncol Pharm Pract; 2020 Jan; 26(1):244-251. PubMed ID: 31068087
[TBL] [Abstract][Full Text] [Related]
8. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
Ratra A; Dasanu CA
J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
[TBL] [Abstract][Full Text] [Related]
9. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
10. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
[TBL] [Abstract][Full Text] [Related]
11. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
12. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
13. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.
Vermeulen OCB; Brouwer E; Slart RHJA; Sandovici M; Rutgers A; Hilterman TJ; Hiddinga B; Oosting SF; Jalving M; de Heij AH; Knapen DG; Hospers GAP; van der Geest KSM
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38335930
[TBL] [Abstract][Full Text] [Related]
15. Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
Loupret T; Boisseau R; Lopez JG; Bertin P; Vergne-Salle P
In Vivo; 2024; 38(3):1451-1453. PubMed ID: 38688588
[TBL] [Abstract][Full Text] [Related]
16. Pseudo-Progression of Melanoma Treated with Nivolumab/Ipilimumab: A Case Report.
Cuevas Velazquez AM; Ng WL; Calderón Martínez EJ; Yeruva SLH
Am J Case Rep; 2023 Aug; 24():e940954. PubMed ID: 37545116
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
Johnson ED; Kerrigan K; Butler K; Patel SB
J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica.
Liew DFL; Mackie SL; Tison A; Sattui SE; Yates M; Buchanan RRC; Owen CE
Rheum Dis Clin North Am; 2024 May; 50(2):255-267. PubMed ID: 38670724
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
20. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
Kosche C; Stout M; Sosman J; Lukas RV; Choi JN
Melanoma Res; 2020 Jun; 30(3):313-316. PubMed ID: 31567590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
